HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of automated peritoneal dialysis within a peritoneal dialysis program.

Abstract
We wished to assess the impact of automated peritoneal dialysis (APD) on the peritoneal dialysis (PD) program. From November 1981 to December 1993, 112 patients were started on hemodialysis (HD) as first treatment and 88 on PD [continuous ambulatory peritoneal dialysis (CAPD): 78, APD: 10]; respective average ages were 61 +/- 14 and 62 +/- 13 years. To December 1985, APD was used as first treatment of PD in 1/29 patients (3.4%), while subsequently, on the basis of a clinical and social-aptitude assessment protocol, it was used in 9/59 patients (15.2%) with PD indication and CAPD contraindications (work: 2 patients, partner required: 7 patients). Of the patients who interrupted CAPD, APD was used in 9/21 patients (reason: social aptitude, 28.6%; clinical, 71.4%). Technique survival after 5 years proved no different in HD versus PD (87% vs 82%, p = NS), whereas in HD versus CAPD it was different (87% vs 62%, p < 0.025). The incidence of peritonitis in APD and CAPD with the Y-set was comparable (1/37 vs 1/40 episode/patient-months), while germ distribution was different (p < 0.001) with Staphylococcus epidermidis prevailing in APD (59%). Based on our experience, APD may extend method acceptance criteria and reduce the technique dropout rate in PD; however, connection technique may need to be improved in order to reduce the risk of peritonitis from exogenous contamination.
AuthorsG Viglino, C Gandolfo, G Virga, P L Cavalli
JournalAdvances in peritoneal dialysis. Conference on Peritoneal Dialysis (Adv Perit Dial) Vol. 11 Pg. 134-8 ( 1995) ISSN: 1197-8554 [Print] Canada
PMID8534687 (Publication Type: Journal Article)
Topics
  • Automation
  • Humans
  • Middle Aged
  • Patient Compliance
  • Peritoneal Dialysis (adverse effects, methods)
  • Peritoneal Dialysis, Continuous Ambulatory (adverse effects)
  • Peritonitis (etiology)
  • Renal Dialysis
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: